Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy (HCM is a complex, yet relatively common, genetic heart disease that occurs in approximately 1 in 500 individuals. It affects both genders and all races. The disease results in excessive thickening of the heart muscle—referred to as “hypertrophy”—which occurs most commonly in the septum (i.e. the muscular wall that separates the left and right lower chambers of the heart). In the majority of patients, this thickening begins during puberty, with little to no change in the thickness beyond early adulthood. However, symptoms from HCM can develop or worsen at any age, but most commonly occur during mid-life.

Doctors + Care Team

Carey D. Kimmelstiel, MD
Request Appointment for Carey D. Kimmelstiel, MD

Carey D. Kimmelstiel, MD

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Director, Interventional Cardiology Center; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-2273
Fax #: 617-636-5913

Interventional cardiology

View Full Profile for Carey D. Kimmelstiel, MD
picture of Lawrence S. Lee, MD, MBA

Lawrence S. Lee, MD, MBA

Title(s): Surgical Director, Structural Heart Program, Tufts Medical Center
Visiting Associate Professor, Tufts University School of Medicine
Department(s): CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Coronary artery disease, valve disease, atrial fibrillation, arrhythmia, hypertrophic cardiomyopathy, minimally invasive and hybrid therapies

View Full Profile for Lawrence S. Lee, MD, MBA

Research + Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-G20 in Subjects with Hypertrophic Obstructive Cardiomyopathy

This will be a double-blinded, placebo-controlled study, aiming to assess the safety and tolerability of CT-G20 in subjects with obstructive hypertrophic cardiomyopathy (oHCM).
More information about research and clinical trials

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients with Non-obstructive Hypertrophic Cardiomyopathy

This study is a double-blinded phase 2 clinical trial for a medication dedicated to treating patients with non-obstructive hypertrophic cardiomyopathy.
More information about research and clinical trials